🔴 Outlook Therapeutics is trading 5.5% down today after Q3 revenue fell to $9 thousand

Outlook Therapeutics is trading at $0.71, down -5.54%, after weak Q3 revenue and recent financing.

• Q3 revenue was only $9 thousand, versus $1.505 million a year earlier.
• The company recently raised approximately $51.1 million net, issuing shares and warrants at $0.99.
• Management still targets a U.S. LYTENAVA launch before December 31, 2026.